AI Article Synopsis

  • Aryl hydrocarbon receptor (AhR) antagonism, specifically through the administration of trimethoxyflavone (TMF), showed potential in reducing brain damage from ischaemia and reperfusion injury in a rat stroke model.
  • MRI results indicated that TMF treatment significantly resulted in fewer brain infarcts and improved diffusion values compared to the control group, highlighting the neuroprotective benefits of early TMF administration.
  • The timing of AhR antagonist (TMF) administration was crucial, with treatment given 10 minutes post-ischaemia yielding better outcomes in reducing cellular damage than treatment given 50 minutes later.

Article Abstract

Aryl hydrocarbon receptor (AhR) antagonism can mitigate cellular damage associated with cerebral ischaemia and reperfusion (I/R) injury. This study investigated the neuroprotective effects of AhR antagonist administration before reperfusion in a rat stroke model and influence of the timing of AhR antagonist administration on its neuroprotective effects. Magnetic resonance imaging (MRI) was performed at baseline, immediately after, and 3, 8, and 24 h after ischaemia in the sham, control (I/R injury), TMF10 (trimethoxyflavone [TMF] administered 10 min post-ischaemia), and TMF50 (TMF administered 50 min post-ischaemia) groups. The TMF treatment groups had significantly fewer infarcts than the control group. At 24 h, the relative apparent diffusion coefficient values of the ischaemic core and peri-infarct region were significantly higher and relative T2 values were significantly lower in the TMF10 groups than in the control group. The TMF treatment groups showed significantly fewer terminal deoxynucleotidyl transferase dUTP nick-end labelling positive (+) cells (%) in the peri-infarct region than the control group. This study demonstrated that TMF treatment 10 or 50 min after ischaemia alleviated brain damage. Furthermore, the timing of AhR antagonist administration affected the inhibition of cellular or vasogenic oedema formation caused by a transient ischaemic stroke.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7483549PMC
http://dx.doi.org/10.1038/s41598-020-72023-5DOI Listing

Publication Analysis

Top Keywords

ahr antagonist
12
antagonist administration
12
tmf treatment
12
control group
12
aryl hydrocarbon
8
hydrocarbon receptor
8
i/r injury
8
neuroprotective effects
8
timing ahr
8
treatment groups
8

Similar Publications

Article Synopsis
  • Anticholinergic drugs may lead to cognitive impairment, and this study specifically examined their risk of causing dementia in older adults in Japan compared to beta-3 agonists.
  • The study involved over 1.4 million participants, with nearly 13,500 taking anticholinergics and around 24,700 using beta-3 agonists, all aged 65 and older with overactive bladder.
  • Results indicated that users of anticholinergic drugs had a 22% higher risk of developing dementia compared to those using beta-3 agonists, suggesting a significant association between anticholinergic use and increased dementia risk.
View Article and Find Full Text PDF

Targeting AhR suppresses hepatocyte ferroptosis in MASH by regulating the Pten/Akt/β catenin axis.

Biochem Pharmacol

December 2024

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Nanjing University of Chinese Medicine, Nanjing 210029, China. Electronic address:

Aryl hydrocarbon Receptor (AhR), an essential host regulator, has been observed to be significantly upregulated in patients with Metabolic dysfunction-associated steatohepatitis (MASH). However, the underlying mechanism remains unclear. The specific AhR antagonist CH223191 and siRNAs were employed to investigated the role of AhR and its potential as a therapeutic target for MASH in mice and hepatocytes model.

View Article and Find Full Text PDF

Triclosan (TCS) is commonly used worldwide due to its bactericidal and antifungal properties. There are data suggesting the involvement of aryl hydrocarbon receptors (AhR) and peroxisome proliferator-activated receptors (PPARγ). Since the effect of TCS on mouse fibroblasts has not been described so far, we decided to investigate the mechanism of action of this compound in the mouse embryonic fibroblast cell line (3T3-L1).

View Article and Find Full Text PDF

Poor clinical outcomes associated to multimorbidity, frailty and malnutrition in patients with atrial fibrillation.

J Nutr Health Aging

November 2024

Department of Hematology, Hospital Clínico Universitario Virgen de la Arrixaca, University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain.

Article Synopsis
  • A study was conducted on atrial fibrillation (AF) patients starting vitamin K antagonist (VKA) therapy to determine the effect of comorbidities, frailty, and malnutrition on clinical outcomes.
  • The research found that a majority of patients had multiple health issues, and frailty significantly increased the risks for major bleeding and death, while malnutrition heightened the risk for strokes and overall mortality.
  • These findings underline the importance of addressing these factors in AF patients to improve their health outcomes during VKA treatment.
View Article and Find Full Text PDF

Risk of incident genitourinary cancer following hematuria in patients with atrial fibrillation receiving oral anticoagulants.

Heart Rhythm

November 2024

Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:

Background: Hematuria is common in patients with atrial fibrillation (AF) on oral anticoagulants (OACs). However, risks of incident genitourinary (GU) malignancy and detailed etiologies of hematuria have not been well studied.

Objective: We aimed to investigate the risk of hematuria and underlying GU malignancy in patients with AF receiving OACs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!